Ingemar Turesson
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments 97
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 36
- Oncology top 0.5%
- Cancer Treatment and Pharmacology 27
- Peptidase Inhibition and Analysis 19
- Molecular Biology top 1%
- Protein Degradation and Inhibitors 21
- Glycosylation and Glycoproteins Research 12
-
- Lymphoma Diagnosis and Treatment 14
-
- Monoclonal and Polyclonal Antibodies Research 12
- Co-authors
- Ola LandgrenSigurður Y. KristinssonMagnus BjörkholmLynn R. GoldinJan WestinCecilie BlimarkUlf‐Henrik MellqvistBrian G.M. Durie
- Cited by
- HematologyGeneticsOncology
- Journals
- New England Journal of Medicine (1 paper)Nature Communications (1 paper)Journal of Clinical Oncology (4 papers)
- Partner nations
- SwedenUnited StatesIceland
In The Last Decade
Ingemar Turesson
144 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Hematology 6.2k
- Genetics 1.8k
- Oncology 3.5k
- Molecular Biology 4.0k
- Pathology and Forensic Medicine 860
Countries citing papers authored by Ingemar Turesson
This map shows the geographic impact of Ingemar Turesson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingemar Turesson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingemar Turesson more than expected).
Fields of papers citing papers by Ingemar Turesson
This network shows the impact of papers produced by Ingemar Turesson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingemar Turesson. The network helps show where Ingemar Turesson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ingemar Turesson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 3 | |
| 4 | 2021 | 11 | |
| 5 | 2021 | 4 | |
| 6 | 2021 | 7 | |
| 7 | 2019 | 1 | |
| 8 | 2017 | 2 | |
| 9 | 2015 | 124 | |
| 10 | 2014 | 12 | |
| 11 | 2011 | 179 | |
| 12 | 2011 | 93 | |
| 13 | 2009 | 101 | |
| 14 | 2009 | 24 | |
| 15 | A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity | 2008 | 16 |
| 16 | 2007 | 99 | |
| 17 | 2002 | 45 | |
| 18 | Involvement and intrinsic deficiencies of hematopoietic stem cells in MDS patients with trisomy 8 | 2001 | 2 |
| 19 | 2000 | 203 | |
| 20 | 1996 | 2 |
About Ingemar Turesson
Ingemar Turesson is a scholar working on Hematology, Genetics and Oncology, having authored 148 papers that have together received 8.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (97 papers), Chronic Lymphocytic Leukemia Research (36 papers), Cancer Treatment and Pharmacology (27 papers), Protein Degradation and Inhibitors (21 papers), Peptidase Inhibition and Analysis (19 papers), Lymphoma Diagnosis and Treatment (14 papers), Glycosylation and Glycoproteins Research (12 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). The work is most often cited by research in Hematology (6.2k citations), Genetics (1.8k citations) and Oncology (3.5k citations). Ingemar Turesson has collaborated with scholars based in Sweden, United States and Iceland. Frequent co-authors include Ola Landgren, Sigurður Y. Kristinsson, Magnus Björkholm, Lynn R. Goldin, Jan Westin, Cecilie Blimark, Ulf‐Henrik Mellqvist, Brian G.M. Durie, Kazuyuki Shimizu and Gareth J. Morgan. Their work appears in journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.